Patent: 7,067,539
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 7,067,539
Title: | Cannabinoid receptor ligands |
Abstract: | The invention relates to compounds of the formula ##STR00001## a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions. |
Inventor(s): | Kozlowski; Joseph A. (Princeton, NJ), Shih; Neng-Yang (North Caldwell, NJ), Lavey; Brian J. (Chatham, NJ), Rizvi; Razia K. (Bloomfield, NJ), Shankar; Bandarpalle B. (Branchburg, NJ), Spitler; James M. (Westfield, NJ), Tong; Ling (Warren, NJ), Wolin; Ronald L. (San Diego, CA), Wong; Michael K. (North Brunswick, NJ) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Application Number: | 10/214,897 |
Patent Claims: | see list of patent claims |
Details for Patent 7,067,539
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | See Plans and Pricing | 2021-02-08 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | See Plans and Pricing | 2021-02-08 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | See Plans and Pricing | 2021-02-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |